Axsome Therapeutics, a clinical-stage biopharmaceutical company, completed the acquisition of Sunosi, a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living, from Jazz Pharmaceuticals, a global biopharmaceutical company, for $53m. "This transaction advances our efforts to deliver sustainable growth, enhanced shareholder value and drive the transformation of Jazz to an innovative, global biopharmaceutical leader. Jazz will continue to be laser-focused on investing in our highest strategic priorities including our ongoing launches, advancing our pipeline, pursuing opportunistic corporate development and achieving margin expansion. Through our development and launch of Sunosi, the Jazz team has laid the foundation for Axsome to continue supporting people who may benefit from this much-needed treatment," Bruce Cozadd, Jazz Pharmaceuticals Chairman and CEO.